Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 10/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PLEC | Q15149 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22908891 | 0.90 | PRSS1 (0.69) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL22428322 | 0.87 | PRSS1 (0.71) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL29512975 | 0.87 | PRSS1 (0.71) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL29513036 | 0.87 | PRSS1 (0.71) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL22908881 | 0.87 | PRSS1 (0.71) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL22121248 | 0.86 | PRSS1 (0.55) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL22118804 | 0.84 | GAA (0.58) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL6023401 | 0.83 | PRSS1 (0.47) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL22135331 | 0.81 | PRSS1 (0.59) | PRSS1PTGER4GAAKDM4EALDH1A1 | |
| SCHEMBL7513506 | 0.79 | PKM (0.67) | PRSS1PTGER4GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138420-B2 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050203158-A1 | Substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1529046-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014905-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203158-A1 | Substituted benzimidazole compounds | ITK, BLK, SBK1 | PRSS1 515/4885PTGER4 1117/4885GAA 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.